The stock has a 36-month beta value of 0.79. Opinions on the stock are mixed, with 10 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for LRMR is 36.46M, and at present, short sellers hold a 17.48% of that float. On June 25, 2025, the average trading volume of LRMR was 1.26M shares.
LRMR) stock’s latest price update
Larimar Therapeutics Inc (NASDAQ: LRMR)’s stock price has plunge by 2462757relation to previous closing price of 2.42. Nevertheless, the company has seen a 3.46% surge in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-23 that Interactions with FDA over the past year have provided clear expectations for the path to submission of the nomlabofusp BLA Written FDA recommendations for safety database include a total of at least 30 participants with continuous exposure for 6 months including a subset of at least 10 with 1-year; large majority of the exposure should be on the 50 mg dose BLA submission seeking accelerated approval planned in the second quarter of 2026 to allow for inclusion of the recommended safety data for adults and children OLE data expected in September 2025 from 30-40 participants who received at least one dose of nomlabofusp; data will include participants on the 50 mg dose Adolescent PK run-in data expected in September 2025 from 14 participants (some on placebo); participants currently screening and enrolling into OLE Global Phase 3 study activities are ongoing with identification and qualification of sites in U.S., Europe, U.K., Canada, and Australia Company management to host webcast and conference call today at 8:00 a.m. ET BALA CYNWYD, Pa.
LRMR’s Market Performance
Larimar Therapeutics Inc (LRMR) has seen a 3.46% rise in stock performance for the week, with a 54.92% gain in the past month and a 31.14% surge in the past quarter. The volatility ratio for the week is 12.92%, and the volatility levels for the past 30 days are at 7.54% for LRMR. The simple moving average for the past 20 days is 16.44% for LRMR’s stock, with a -31.34% simple moving average for the past 200 days.
Analysts’ Opinion of LRMR
Many brokerage firms have already submitted their reports for LRMR stocks, with Truist repeating the rating for LRMR by listing it as a “Buy.” The predicted price for LRMR in the upcoming period, according to Truist is $18 based on the research report published on January 29, 2025 of the current year 2025.
Oppenheimer, on the other hand, stated in their research note that they expect to see LRMR reach a price target of $26. The rating they have provided for LRMR stocks is “Outperform” according to the report published on October 16th, 2024.
Wedbush gave a rating of “Outperform” to LRMR, setting the target price at $22 in the report published on October 03rd of the previous year.
LRMR Trading at 29.01% from the 50-Day Moving Average
After a stumble in the market that brought LRMR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -73.30% of loss for the given period.
Stock Fundamentals for LRMR
Current profitability levels for the company are sitting at:
- -437.11 for the present operating margin
- 0.33 for the gross margin
The net margin for Larimar Therapeutics Inc stands at -395.15. The total capital return value is set at -0.71. Equity return is now at value -50.77, with -45.52 for asset returns.
Based on Larimar Therapeutics Inc (LRMR), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -17.86.
Currently, EBITDA for the company is -80.29 million with net debt to EBITDA at 0.15. When we switch over and look at the enterprise to sales, we see a ratio of 726.9. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.48.
Conclusion
To sum up, Larimar Therapeutics Inc (LRMR) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
